Christian Pangratz joined Activaero’s management team in April 2011 bringing more than 20 years of life sciences industry experience to the company. Previously, he was Executive Director of Business Development at Nektar Therapeutics in San Francisco. During his seven years at Nektar, Christian also held positions in Marketing, New Product Planning and Alliance Management. Prior to Nektar, Christian served as a Managing Partner at the Vienna Business Development Group and Head of Marketing at Universimed. Earlier in his career, he held regional and international marketing positions at Pfizer and Bayer.
invendo is a privately held medical devices company with the technology site near Munich, Germany, and the commercial site in Garden City, New York. In December 2012, invendo received FDA clearance for the invendoscopy system, a robotic single-use endoscopy system for colorectal cancer prevention, and has meanwhile installed the first units in prestigious US hospitals. The device reduces pain, is easy to operate, and enhances capacity for providers while eliminating sedation cost. The company is currently raising a $30 M financing round that will enable it to go to market in the United States and achieve double-digit $ million sales.
Berthold Hackl – Chief Executive Officer
Mr. Hackl joined invendo medical as Chief Executive Officer in August 2007. He has a 28 years history in the medical device and instrumentation sector, among others with Biacore and Pharmacia (now GE Healthcare) and Synthes (now Johnson&Johnson), and the healthcare VC firm Heidelberg Innovation, where he invested in invendo medical and other device companies. Mr. Hackl obtained his degree in molecular biology from University of Freiburg and holds an MBA from INSEAD.
Dr. Marcus Furch, Co-Founder and CEO
Marcus Furch, chemist by training; received his PhD in the area of Biochemistry from the University of Heidelberg in 1999, followed by an Executive MBA from the Maastricht University Business School. During his scientific and academic career he worked as a research scientist in international and renowned laboratories in Germany (Max-Planck Institute for Medical Research, Heidelberg as well as Hannover Medical School), France (CNRS, Montpellier), Spain (University of the Basque Country in San Sebástian) and the United States (The Scripps Research Institute, La Jolla, California). As management consultant at Brazilian Kienbaum subsidiary Böge Consultores in São Paulo he advised chemical and pharmaceutical companies entering Latin American markets. During five years in business development at Fresenius SE, the global player of pharmaceuticals and medical devices, he was involved in numerous M&A, in-licensing, and partnering transactions. While working with Nalucon in Heidelberg as interim manager and advisor to both companies and investors in the chemical and life-science industry, he joined the founders of RBT.